Unoprostone
Appearance
(Redirected from Rescula)
![]() | |
Clinical data | |
---|---|
Trade names | Rescula |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Topical (eye drops) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 14 min |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.227.145 |
Chemical and physical data | |
Formula | C22H38O5 |
Molar mass | 382.541 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]
It was approved by the Food and Drug Administration in 2000.[3]
In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]
In 2015, the drug was discontinued in the U.S.[citation needed]
References
[edit]- ^ Micromedex Detailed Consumer Information
- ^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
- ^ "Drug Approval Package". Food and Drug Administration.
- ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.